China tuberculosis diagnosis and treatment market is anticipated to grow at a CAGR around 3.1% during the forecast period. China being the largest populated country has the world’s second largest burden of multidrug-resistant tuberculosis. Government initiatives play an important role in market growth as they are responsible for large adoption of tuberculosis diagnosis and treatment. China launched the 10 year Infectious and Endemic Disease Control (IEDC) project in 1991 to curb the TB epidemic in 13 of its 31 mainland provinces. It was funded by a World Bank loan of $58 million and this project adopted the TB DOTS strategy as well as short course drug treatment developed by the World Health Organization (WHO) in 1989. The project set out to improve the finding of new smear positive cases from 35% to 70%.
To Request a Sample of our Report on China Tuberculosis Diagnosis and Treatment Market: https://www.omrglobal.com/request-sample/china-tuberculosis-diagnosis-treatment-market
China tuberculosis diagnosis and treatment market is segmented on the basis of drugs type and diagnosis. Based on drug type, the market is segmented into first line drugs and second line drugs. Based on diagnosis, the market is segmented into laboratory testing, nucleic acid amplification test, mantoux test, radiography and drug susceptibility testing.
(Get 15% Discount on Buying this Report)
A full Report of China Tuberculosis Diagnosis and Treatment Market is Available at: https://www.omrglobal.com/industry-reports/china-tuberculosis-diagnosis-treatment-market
China Tuberculosis Diagnosis and Treatment Market Segmentation
By Drugs Type
- First Line Drugs
- Second Line Drugs
By Diagnosis
- Laboratory Testing
- Nucleic Acid Amplification Test
- Mantoux Test
- Radiography
- Drug Susceptibility Testing
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
